Advertisement
UK markets open in 4 hours 50 minutes

  • NIKKEI 225

    37,757.90
    -702.18 (-1.83%)
     

  • HANG SENG

    17,217.18
    +15.91 (+0.09%)
     

  • CRUDE OIL

    82.65
    -0.16 (-0.19%)
     

  • GOLD FUTURES

    2,331.10
    -7.30 (-0.31%)
     

  • DOW

    38,460.92
    -42.77 (-0.11%)
     

  • Bitcoin GBP

    51,497.21
    -2,012.29 (-3.76%)
     

  • CMC Crypto 200

    1,389.44
    -34.66 (-2.43%)
     

  • NASDAQ Composite

    15,712.75
    +16.11 (+0.10%)
     

  • UK FTSE All Share

    4,374.06
    -4.69 (-0.11%)
     
Money:

The five essential pieces of financial paperwork you must never lose

Mislaying key documents can cause real headaches, so it’s worth tracking down these most commonly-lost bits of paperwork

FDA staff question utility of Novo Nordisk combo diabetes drug

Reuters - UK Focus

May 20 (Reuters) - A preliminary review by the U.S (Other OTC: UBGXF - news) . Food and Drug Administration of Novo Nordisk A/S (LSE: 0QIU.L - news) 's experimental diabetes drug, IDegLira, questioned the interpretability of the study findings and practical utility of the treatment, according to a review posted on the agency's website on Friday.

The review comes ahead of a May 24 meeting of an FDA advisory panel that will meet to discuss the drug and make recommendations as to whether it should be approved. The FDA is not obliged to follow the advice of its advisory panels but typically does so. (Reporting by Toni Clarke in Washington)